Profound Medical to Release Third Quarter 2024 Financial Results on November 7 – Conference Call to Follow
Profound Medical Corp. (NASDAQ:PROF; TSX:PRN), a commercial-stage medical device company specializing in incision-free therapies for diseased tissue ablation, has announced it will release its third quarter 2024 financial results after market close on Thursday, November 7, 2024. The company will host a conference call at 4:30 p.m. ET on the same day to discuss the financial results and business developments.
Investors and interested parties can register for the live call at the provided link. The call will also be broadcast live and archived on Profound's website under the 'Webcasts' section in the Investors area.
Profound Medical Corp. (NASDAQ:PROF; TSX:PRN), una società medica in fase commerciale specializzata in terapie senza incisione per l'ablazione dei tessuti malati, ha annunciato che rilascerà i risultati finanziari del terzo trimestre 2024 dopo la chiusura del mercato il giovedì 7 novembre 2024. L'azienda ospiterà una call di conferenza alle 16:30 ET lo stesso giorno per discutere i risultati finanziari e gli sviluppi aziendali.
Gli investitori e le parti interessate possono registrarsi per la chiamata dal vivo al link fornito. La chiamata sarà anche trasmessa in diretta e Archiviata sul sito web di Profound nella sezione 'Webcasts' nell'area Investitori.
Profound Medical Corp. (NASDAQ:PROF; TSX:PRN), una compañía de dispositivos médicos en etapa comercial especializada en terapias sin incisión para la ablación de tejidos enfermos, ha anunciado que publicará sus resultados financieros del tercer trimestre de 2024 después del cierre del mercado el jueves 7 de noviembre de 2024. La empresa realizará una llamada de conferencia a las 4:30 p.m. ET el mismo día para discutir los resultados financieros y los desarrollos comerciales.
Los inversores y partes interesadas pueden registrarse para la llamada en vivo a través del enlace proporcionado. La llamada también se transmitirá en vivo y se archivará en el sitio web de Profound en la sección 'Webcasts' en el área de Inversores.
Profound Medical Corp. (NASDAQ:PROF; TSX:PRN)은 상업 단계의 의료 기기 회사로, 절개 없는 질병 조직 절제 치료법을 전문으로 하고 있으며, 2024년 3분기 재무 결과를 2024년 11월 7일 목요일 주식 시장 마감 후 발표할 것이라고 발표했습니다. 회사는 같은 날 동부 표준시 오후 4시 30분에 재무 결과 및 비즈니스 개발에 대해 논의하기 위한 컨퍼런스 콜을 주최합니다.
투자자 및 관심 있는 당사자는 제공된 링크를 통해 라이브 콜에 등록할 수 있습니다. 이 통화는 라이브로 방송되며, Profound의 웹사이트 'Webcasts' 섹션의 투자자 영역에 아카이브됩니다.
Profound Medical Corp. (NASDAQ:PROF; TSX:PRN), une entreprise de dispositifs médicaux en phase commerciale spécialisée dans les thérapies sans incision pour l'ablation des tissus malades, a annoncé qu'elle publiera ses résultats financiers du troisième trimestre 2024 après la clôture du marché le jeudi 7 novembre 2024. L'entreprise organisera une conférence téléphonique à 16h30 ET le même jour pour discuter des résultats financiers et des développements commerciaux.
Les investisseurs et les parties intéressées peuvent s'inscrire à l'appel en direct via le lien fourni. L'appel sera également diffusé en direct et archivé sur le site Web de Profound dans la section 'Webcasts' dans la zone Investisseurs.
Profound Medical Corp. (NASDAQ:PROF; TSX:PRN), ein unternehmen für medizinische Geräte in der kommerziellen Phase, das sich auf einschnittfreie Therapien zur Ablation erkrankten Gewebes spezialisiert hat, hat angekündigt, dass die Finanzergebnisse für das dritte Quartal 2024 nach Marktschluss am Donnerstag, den 7. November 2024 veröffentlicht werden. Das Unternehmen wird an diesem Tag um 16:30 Uhr ET eine Telefonkonferenz abhalten, um die Finanzergebnisse und Geschäftsentwicklungen zu erörtern.
Investoren und interessierte Parteien können sich über den bereitgestellten Link für den Live-Anruf registrieren. Der Anruf wird auch live über das Internet übertragen und im Bereich 'Webcasts' auf der Investorenseite von Profound archiviert.
- None.
- None.
TORONTO, Oct. 17, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, will announce its third quarter 2024 financial results after market close on Thursday, November 7, 2024.
Profound management will host a conference call at 4:30 p.m. ET to review the financial results and discuss business developments in the period.
Third Quarter 2024 Results Conference Call Details:
| Date: | Thursday, November 7, 2024 | |
| Time: | 4:30 p.m. ET | |
| Live Call Registration: | https://register.vevent.com/register/BI0b43a811a8b64fc1a7f58af602ccc933 |
The call will also be broadcast live and archived on the Company's website at www.profoundmedical.com under "Webcasts" in the Investors section.
About Profound Medical Corp.
Profound is a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue.
Profound is commercializing TULSA-PRO®, a technology that combines real-time MRI, robotically-driven transurethral ultrasound and closed-loop temperature feedback control. The TULSA procedure, performed using the TULSA-PRO® system, has the potential of becoming a mainstream treatment modality across the entire prostate disease spectrum; ranging from low-, intermediate-, or high-risk prostate cancer; to hybrid patients suffering from both prostate cancer and benign prostatic hyperplasia (“BPH”); to men with BPH only; and also, to patients requiring salvage therapy for radio-recurrent localized prostate cancer. TULSA employs real-time MR guidance for pixel-by-pixel precision to preserve prostate disease patients’ urinary continence and sexual function, while killing the targeted prostate tissue via a precise sound absorption technology that gently heats it to kill temperature (55-57°C). TULSA is an incision- and radiation-free “one-and-done” procedure performed in a single session that takes a few hours. Virtually all prostate shapes and sizes can be safely, effectively, and efficiently treated with TULSA. There is no bleeding associated with the procedure; no hospital stay is required; and most TULSA patients report quick recovery to their normal routine. TULSA-PRO® is CE marked, Health Canada approved, and 510(k) cleared by the U.S. Food and Drug Administration (“FDA”).
Profound is also commercializing Sonalleve®, an innovative therapeutic platform that is CE marked for the treatment of uterine fibroids and palliative pain treatment of bone metastases. Sonalleve® has also been approved by the China National Medical Products Administration for the non-invasive treatment of uterine fibroids and has FDA approval under a Humanitarian Device Exemption for the treatment of osteoid osteoma. The Company is in the early stages of exploring additional potential treatment markets for Sonalleve® where the technology has been shown to have clinical application, such as non-invasive ablation of abdominal cancers and hyperthermia for cancer therapy.
For further information, please contact:
Stephen Kilmer
Investor Relations
skilmer@profoundmedical.com
T: 647.872.4849
FAQ
When will Profound Medical (PROF) release its Q3 2024 financial results?
What time is Profound Medical's (PROF) Q3 2024 earnings conference call?
How can I access Profound Medical's (PROF) Q3 2024 earnings call?
What does Profound Medical (PROF) specialize in?
